Blockchain Registration Transaction Record

Soligenix Wins EU Orphan Drug Status for Behcet's Disease Therapy

Soligenix receives EU orphan drug designation for dusquetide (SGX945) to treat Behcet's Disease, providing 10 years of market exclusivity and advancing rare disease therapy.

This development matters because Behcet's Disease is a rare, chronic autoimmune disorder that causes painful inflammation in blood vessels throughout the body, leading to severe mouth and genital ulcers, skin lesions, and potentially blindness or stroke. With limited treatment options available, patients often face a lifetime of debilitating symptoms and complications. The orphan drug designation for dusquetide accelerates its development pathway, providing regulatory incentives and market exclusivity that make it economically viable for companies to invest in rare disease research. For the estimated 1 in 100,000 people affected by Behcet's Disease in Europe and North America, this represents hope for a more effective, targeted therapy that could significantly improve quality of life. Furthermore, success with dusquetide validates Soligenix's innate defense regulator platform, which could potentially be applied to other inflammatory conditions, expanding treatment possibilities beyond this specific rare disease.